Sugi Predict
/ Targets
/ REV1
Top predicted compounds (top 20 by supporting neighbours, then confidence)
Clinical trials — most relevant to REV1 by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| S0720: Adjuvant Therapy Based on Gene Expression in Stage IA and IB Non-Small Cell Lung Cancer |
PHASE2 | COMPLETED |
| Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer |
PHASE2 | WITHDRAWN |
| Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath Tumor |
PHASE1/PHASE2 | NOT_YET_RECRUITING |
| S0356 Oxaliplatin, 5-FU, Radiation Therapy (RT), Surgery for Pts With Stage II or III Cancer of Esophagus or Gastroesophageal (GE) Junction |
PHASE2 | COMPLETED |
| Satraplatin and Prednisone to Treat Prostate Cancer |
PHASE2 | COMPLETED |
| Phase II ABT-888 With Cyclophosphamide |
PHASE2 | COMPLETED |
| A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies |
PHASE1/PHASE2 | RECRUITING |
| Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas |
PHASE1 | COMPLETED |
| Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer |
PHASE1 | COMPLETED |
| Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors |
PHASE1 | COMPLETED |
| A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors |
PHASE1 | COMPLETED |
| Indenoisoquinoline LMP400 for Advanced Solid Tumors and Lymphomas |
PHASE1 | COMPLETED |
| Nucleoside Therapy in Patients With Telomere Biology Disorders |
PHASE1 | RECRUITING |
| A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors |
PHASE1 | COMPLETED |
| Gemcitabine and Radiation Therapy in Treating Patients With Locally Advanced Upper Gastrointestinal Cancer |
PHASE1 | COMPLETED |
| A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients |
nan | COMPLETED |
| Genetic Polymorphisms in UGT1A6 and UGT2B7 in Asian Population: Association With Lung Cancer Phenotype |
nan | UNKNOWN |
| Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics |
nan | UNKNOWN |
| Thymidine Kinase 1 in Risk Assessment for Hereditary Breast /Ovarian Cancer |
nan | UNKNOWN |
| DNA Repair Genes and Outcomes in Patients With Stage III NSCLC |
nan | UNKNOWN |
| DNA Damage & Repair Proteins In Patients With Atherosclerotic Coronary Artery Disease |
nan | COMPLETED |
| MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy |
nan | UNKNOWN |
| Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia |
nan | NOT_YET_RECRUITING |
| Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors |
nan | COMPLETED |
| Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With Nicotinamide Riboside |
nan | UNKNOWN |
| Pesticide Associated Lymphomas: Expression of Treatment Resistance Genes |
nan | COMPLETED |
| Nicotinamide Riboside and Mitochondrial Biogenesis |
nan | COMPLETED |
| Chronic Cough and CANVAS (Cerebellar Ataxia With Neuropathy and Bilateral Vestibular Areflexia Syndrome) |
nan | COMPLETED |
| The Genetic and the Functional Study of DNA Repair System and the Susceptibility to Rheumatoid Arthritis |
nan | COMPLETED |
Related proteins — ESM-2 sequence neighbours (a REV1 binder may also engage these)